NKTR-255

NKTR-255

RESEARCH FOCUS: Immuno-oncology

Preclinical

About NKTR-255

NKTR-255 is an IL-15 receptor agonist designed to engage the IL-15 pathway to stimulate and expand natural killer (NK) cells and promote the survival and expansion of central memory CD8+ T cells without inducing suppressive regulatory T cells. Through optimal engagement of the IL-15Rα/IL-2Rγ receptor complex, NKTR-255 enhances formation of long-term immunological memory which may lead to sustained anti-tumor immune response. Native rhIL-15 is rapidly cleared from the body and must be administered frequently and in high doses limiting its utility due to toxicity. NKTR-255 is designed with IL-15 receptor alpha specificity to optimize biological activity and is uniquely engineered to provide optimal exposure and an improved safety profile.

In oncology, NKTR-255 is currently being evaluated in preclinical studies in combination with targeted antibody therapies in lymphoma and multiple myeloma. Through a collaboration with Fred Hutchinson Cancer Center, NKTR-255 is being evaluated in combination with CAR-T therapy in preclinical studies. NKTR-255 will also be explored in combination with anti-retroviral and immune modulator therapies through a research collaboration with Gilead.

2018 ASH 60th Annual Meeting

SITC 2018

2018 American Conference on Pharmacometrics (ACoP), San Diego, CA

CHI 3rd Annual NK Cell-Based Cancer Immunotherapy Conference, Boston, MA

CHI 2nd Annual Emerging Immuno-Oncology Targets Conference, Boston, MA

Society for Immunotherapy in Cancer (SITC) 32nd Annual Meeting, National Harbor, MD

2017 American Association for Cancer Research (AACR) Annual Meeting

2016 SITC Annual Meeting